Bio Pharma Dive

JULY 14, 2023

The pharma will pay up to $1.9 billion to acquire the private biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines.

Antibody 246

Antibody Drugs Medicine 246

Pharmaceutical Technology

JULY 14, 2023

Vistagen has received a Canadian Notice of Allowance for patent that is related to the use of AV-101 in Parkinson's disease (PD) patients.

130

130

Bio Pharma Dive

JULY 14, 2023

The deal with Frequency Therapeutics is the latest biotech reverse merger as private drugmakers still face challenges going public via an IPO.

RNA 246

RNA 246

Pharmaceutical Technology

JULY 14, 2023

Gilead Sciences has entered into collaborations with CHAI and Penta ID network to expedite the development of dispersible HIV treatments.

Development 130

Development 130

Advertisement

Clinical Supply

Bio Pharma Dive

JULY 14, 2023

Industry watchers have predicted the second half of 2023 could be busier for biotech IPOs despite a slow start to the year.

Marketing 130

Marketing 130

Pharmaceutical Technology

JULY 14, 2023

AstraZeneca and Merck have received conditional approval from Health Canada for Lynparza (olaparib) combination to treat prostate cancer.

130

130

Pharmaceutical Technology

JULY 14, 2023

Theseus Pharmaceuticals has terminated its pan-variant tyrosine kinase receptor (KIT) inhibitor (THE-630) drug development programme.

Development 130

Development Drugs 130

Antidote

JULY 14, 2023

For medical research to advance, the participation of individuals in a clinical trial is essential. However, accessing trial sites can present an undue burden. A survey about barriers to clinical trial participation found that the primary reason patients declined to enroll in a study was due to the inconvenience associated with travel. This is backed up by research from Deloitte, which reveals that 70% of potential clinical trial participants in the United States live at least two hours away fro

Clinical Trials 98

Clinical Trials Clinical Trials Trials Research 98

Pharmaceutical Technology

JULY 14, 2023

Emmaus Life Sciences has received marketing authorisation for Endari (L-glutamine oral powder) in Oman for sickle cell disease.

Marketing 130

Marketing Life Science 130

Pharma Times

JULY 14, 2023

CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma - News - PharmaTimes

Research 108

Research 108

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharmaceutical Technology

JULY 14, 2023

The offering follows recent lucrative deals with Novartis and Bayer for the use of Bicycle Therapeutics’ peptide technology.

130

130

Pharma Times

JULY 14, 2023

Collaboration will focus on progressing test for early detection of Alzheimer’s dementia - News - PharmaTimes

101

101

Pharmaceutical Technology

JULY 14, 2023

Causaly serves 12 of the top 20 pharmaceutical companies with technology that aims to expedite the drug discovery process.

Drugs 130

Drugs 130

Fierce Pharma

JULY 14, 2023

As Johnson & Johnson awaits a decision on its second attempt to resolve talc lawsuits through a bankruptcy ploy, the company is attempting another legal tactic to free itself from those liabili | As Johnson & Johnson awaits a decision on its second attempt to resolve talc lawsuits through a bankruptcy ploy, the company is attempting another legal tactic to help free itself from those liabilities—suing doctors who say that its iconic baby powder can cause cancer.

Doctors 86

Doctors Doctor 86

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Pharmaceutical Technology

JULY 14, 2023

Yusimry is priced at $995 per carton of two autoinjectors compared to Humira’s price tag of $6,922 for the same quantity.

Sales 130

Sales 130

Fierce Pharma

JULY 14, 2023

The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.

Gene Therapy 82

Gene Therapy Gene Medicine 82

Pharmaceutical Technology

JULY 14, 2023

After a call to action on social media, J&J has allowed the generic production of its tuberculosis drug bedaquiline.

Production 130

Production Drugs 130

pharmaphorum

JULY 14, 2023

Changing Faces: Non-profit, professional organisation, and government hires from May & June 2023 Mike.

92

92

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Pharmaceutical Technology

JULY 14, 2023

CureVac adds one more patent to the growing tally in its counterclaim against Pfizer and BioNTech in the US.

130

130

pharmaphorum

JULY 14, 2023

10 ways to start (or continue) your patient engagement journey Mike.

89

89

Intouch Solutions

JULY 14, 2023

The Urgent Need for Action Climate scientists and activists have been tirelessly working to sound the alarm on climate change and its impacts, but despite their efforts, meaningful intervention is too slow in coming. Climate change and health inequities demand immediate attention, and pharma advertisers are uniquely positioned to drive change. Most of us who work in pharma advertising do so because we believe we can make a difference.

Branding 52

Branding Development Packaging Packaging 52

Drug Patent Watch

JULY 14, 2023

Annual Drug Patent Expirations for DUOBRII Duobrii is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are four patents protecting… The post New patent for Bausch drug DUOBRII appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Clinical Supply

Pharmaceutical Commerce

JULY 14, 2023

Recent data and commentary offer insights into how biologics vs. small molecule patent protections under the Inflation Reduction Act pricing scenarios is impacting investing in the biotech sector.

52

52

Drug Patent Watch

JULY 14, 2023

Annual Drug Patent Expirations for PIQRAY Piqray is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting… The post New patent for Novartis drug PIQRAY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

JULY 14, 2023

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery sector, including within the UK itself, with investment into synthetic biology, cell and gene therapy training, cancer drugs and generative AI.

Gene Therapy 52

Gene Therapy Life Science Drugs Gene 52

Drug Patent Watch

JULY 14, 2023

Annual Drug Patent Expirations for ARAZLO Arazlo is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent for Bausch drug ARAZLO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

XTalks

JULY 14, 2023

The US Food and Drug Administration (FDA) has granted clearance to Tandem Diabetes Care, Inc.’s Tandem Mobi insulin pump for individuals six years of age and older with diabetes. Tandem has dubbed The Mobi to be the world’s smallest insulin pump. With a durable automated insulin delivery system, the Tandem Mobi can be completely controlled through a mobile app but also features an on-pump button as an alternative option to bolus insulin doses.

Insulin 52

Insulin Regulation Marketing Drugs 52

Drug Patent Watch

JULY 14, 2023

Annual Drug Patent Expirations for SUNOSI Sunosi is a drug marketed by Axsome Malta and is included in one NDA. It is available from two suppliers. There are ten patents… The post New patent for Axsome Malta drug SUNOSI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

JULY 14, 2023

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, and the company Vivan Therapeutics, a multi-disciplinary team will seek to create drugs that can counteract drug resistance.

Drugs 52

Drugs Research Protein Gene 52

Drug Patent Watch

JULY 14, 2023

Annual Drug Patent Expirations for WYNZORA Wynzora is a drug marketed by MC2 and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent for MC2 drug WYNZORA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Clinical Supply